



RNS Number : 6907A  
EKF Diagnostics Holdings PLC  
01 October 2020

**EKF Diagnostics Holdings plc**  
("EKF" or the "Company")

**Exercise of Options and Total Voting Rights**

**Exercise of options**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted point-of-care business, announces that it has issued and allotted 400,000 new ordinary shares of one pence each in the share capital of the Company ("Ordinary Shares") following an exercise of options on 30 September 2020. The options had an exercise price of 27.25 pence per Ordinary Share.

Application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 400,000 new Ordinary Shares to trading on AIM will become effective on, or around, 6 October 2020 ("Admission").

**Total voting rights**

Following Admission, the Company will have 454,993,227 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 454,993,227.

**Enquiries:**

**EKF Diagnostics Holdings plc**  
Christopher Mills, Non-Executive Chairman  
Julian Baines, CEO  
Richard Evans, FD & COO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
**Tel: 029 2071 0570**

**N+1 Singer (Nomad & Broker)**  
Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate Finance)  
Tom Salvesen (Corporate Broking)

**Tel: 020 7496 3000**

**Walbrook PR Limited**  
Paul McManus/ Lianne Cawthorne

**Tel: 020 7933 8780 or** [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)  
Mob: 07980 541 893 / 07584 391 303

**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well

as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSDWFUSESEDU admin Exercise of Options and Total Voting Rights 31247780 A Thu,  
10/01/2020 - 07:00 LSE RNS Company Announcement - General EKF